Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

HHS finalizes anti-discrimination rule

HHS clarifies that protections against gender discrimination included in the Affordable Care Act apply to gender identity.

FDA changes warning label on fluoroquinolones

Safety review of the drugs associated their use with “disabling and potentially permanent serious side effects” involving tendons, muscles, joints, nerves and the central nervous system.

What we know about Republicans’ ACA replacement

New proposal would include changes to Medicare and Medicaid, but won't be released as actual legislation ahead of the Republican National Convention.

Patients use ProPublica database to find painkiller prescriptions

The investigative news outlet announced its database to track the prescribing habits of doctors has been used by some to find addictive painkillers.

4 changes AHA wants from CMS in implementing new payment system

The American Hospital Association recommended several changes from the proposed requirements in written testimony submitted to the House Ways and Means Committee.

Judge rules Obama admin improperly funding ACA subsidy

A federal judge has ruled HHS and the U.S. Treasury Department don’t have the power to spend funds for reducing deductibles, co-pays and other “cost-sharing” means by insurers without congressional approval.

AMA letter on opioids leaves out recommendations from Senate’s no. 2 Democrat

AMA President Steven Stack, MD, said pain management policies “well-intended but now known to be flawed” have contributed to the increase in abuse of opioid prescription pain relievers

State laws on ‘right-to-try’ experimental drugs backed by new Senate proposal

Legislation would prevent the FDA from restricting or prohibiting access to experimental drugs for a terminal patient in a state with a “right-to-try” law.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.